Cargando…

Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials

Background: The management of drug safety with the collection of reliable safety data during the conduction of clinical trials conduct is essential for the registry and marketing of products. The systematic evaluation of this process, based on objective measures, requires the application of quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Saumell, Yaimarelis, Torres, Olga, Batista, Maritza, Sánchez, Lizet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kerman University of Medical Sciences 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037497/
https://www.ncbi.nlm.nih.gov/pubmed/29996582
http://dx.doi.org/10.15171/ijhpm.2017.140
_version_ 1783338338108833792
author Saumell, Yaimarelis
Torres, Olga
Batista, Maritza
Sánchez, Lizet
author_facet Saumell, Yaimarelis
Torres, Olga
Batista, Maritza
Sánchez, Lizet
author_sort Saumell, Yaimarelis
collection PubMed
description Background: The management of drug safety with the collection of reliable safety data during the conduction of clinical trials conduct is essential for the registry and marketing of products. The systematic evaluation of this process, based on objective measures, requires the application of quality instruments. This study was aimed to design and validate eight instruments through the components of quality (structure, process, and results), for characterizing and assessing the process of drug safety management, during the conduction of clinical trials. Methods: The eight instruments were designed according to the international recommendations for Good Clinical Practice (GCP) and comprise a knowledge survey for professionals at the investigational sites, a satisfaction scale of internal and external clients and a satisfaction survey for patients with the treatment of the adverse events. The instruments also include a checklist to evaluate the safety management infrastructure (human, material and organizational resources) in the sponsoring center, a checklist to evaluate the same criterion at the investigational sites and three checklists that evaluate adherence to regulatory requirements of essential documents (investigator’s brochure, protocol, and informed consent form). The content validity was evaluated by Delphi method and the reliability was determined by Cronbach α test. Results: All the items were valued as very adequate after the second round of the expert panel. The instruments were deemed as appropriate and understandable in the pre-test performed. All responders agreed with the options given and the accessibility of the application. Only 10% of professionals at the research sites suggested that the knowledge survey was too long. Cronbach α values between .66 and .93 were obtained. Conclusion: The structure, process, and outcome framework allowed for the characterization of drug safety management during clinical trials, providing a useful approach for the promoter to systematically measure and evaluate the process. The eight instruments were deemed as reliable, feasible and easy to be used for examining drug safety management while carrying out clinical trials.
format Online
Article
Text
id pubmed-6037497
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Kerman University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-60374972018-07-12 Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials Saumell, Yaimarelis Torres, Olga Batista, Maritza Sánchez, Lizet Int J Health Policy Manag Original Article Background: The management of drug safety with the collection of reliable safety data during the conduction of clinical trials conduct is essential for the registry and marketing of products. The systematic evaluation of this process, based on objective measures, requires the application of quality instruments. This study was aimed to design and validate eight instruments through the components of quality (structure, process, and results), for characterizing and assessing the process of drug safety management, during the conduction of clinical trials. Methods: The eight instruments were designed according to the international recommendations for Good Clinical Practice (GCP) and comprise a knowledge survey for professionals at the investigational sites, a satisfaction scale of internal and external clients and a satisfaction survey for patients with the treatment of the adverse events. The instruments also include a checklist to evaluate the safety management infrastructure (human, material and organizational resources) in the sponsoring center, a checklist to evaluate the same criterion at the investigational sites and three checklists that evaluate adherence to regulatory requirements of essential documents (investigator’s brochure, protocol, and informed consent form). The content validity was evaluated by Delphi method and the reliability was determined by Cronbach α test. Results: All the items were valued as very adequate after the second round of the expert panel. The instruments were deemed as appropriate and understandable in the pre-test performed. All responders agreed with the options given and the accessibility of the application. Only 10% of professionals at the research sites suggested that the knowledge survey was too long. Cronbach α values between .66 and .93 were obtained. Conclusion: The structure, process, and outcome framework allowed for the characterization of drug safety management during clinical trials, providing a useful approach for the promoter to systematically measure and evaluate the process. The eight instruments were deemed as reliable, feasible and easy to be used for examining drug safety management while carrying out clinical trials. Kerman University of Medical Sciences 2017-12-26 /pmc/articles/PMC6037497/ /pubmed/29996582 http://dx.doi.org/10.15171/ijhpm.2017.140 Text en © 2018 The Author(s); Published by Kerman University of Medical Sciences This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Saumell, Yaimarelis
Torres, Olga
Batista, Maritza
Sánchez, Lizet
Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials
title Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials
title_full Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials
title_fullStr Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials
title_full_unstemmed Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials
title_short Validation of Instruments for Assessing Drug Safety Management During the Conduction of Clinical Trials
title_sort validation of instruments for assessing drug safety management during the conduction of clinical trials
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037497/
https://www.ncbi.nlm.nih.gov/pubmed/29996582
http://dx.doi.org/10.15171/ijhpm.2017.140
work_keys_str_mv AT saumellyaimarelis validationofinstrumentsforassessingdrugsafetymanagementduringtheconductionofclinicaltrials
AT torresolga validationofinstrumentsforassessingdrugsafetymanagementduringtheconductionofclinicaltrials
AT batistamaritza validationofinstrumentsforassessingdrugsafetymanagementduringtheconductionofclinicaltrials
AT sanchezlizet validationofinstrumentsforassessingdrugsafetymanagementduringtheconductionofclinicaltrials